The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Multicohort phase II KEYNOTE-059 study of pembrolizumab (MK-3475) for recurrent or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.
 
Charles S. Fuchs
Consulting or Advisory Role - Genentech; Merck; Pfizer; Roche Pharma AG; Sanofi
 
Andrew E. Denker
Employment - Merck Sharp & Dohme
Stock and Other Ownership Interests - Merck Sharp & Dohme
 
Josep Tabernero
Consulting or Advisory Role - Amgen; Celgene; Chugai Pharma; ImClone Systems; Lilly; Merck KGaA; Millennium; Novartis; Roche/Genentech; Sanofi; Symphony Evolution; Taiho Pharmaceutical
 
Eric Van Cutsem
Research Funding - amgen (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Lilly (Inst); Merck Serono (Inst); Novartis (Inst); Roche (Inst); Sanofi (Inst)
 
Atsushi Ohtsu
Employment - Celgene (I)
Honoraria - Chugai Pharma; Daiichi Sankyo; Eisai; Merck Serono; Taiho Pharmaceutical
 
Baohoang Lam
Employment - Kaiser Permanente; Merck
 
Minori Koshiji
Employment - Merck
Stock and Other Ownership Interests - Lilly
 
Yung-Jue Bang
No Relationships to Disclose